STOCK TITAN

[Form 4] Identive, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 highlights for SELECT MEDICAL HOLDINGS CORP (SEM): Executive Vice President Martin F. Jackson was granted 150,000 shares of SEM common stock on 07/29/2025. The shares are restricted stock that will vest in three equal annual tranches (per the footnote) and were issued at a stated price of $0, indicating an equity incentive rather than an open-market purchase.

Following the award, Jackson now holds 1,412,881 shares directly. In addition, he reports 10,536 shares held indirectly for the benefit of his children, which he disclaims except for any pecuniary interest.

No derivative securities were reported in Table II and no sales occurred, so the transaction is purely an equity grant. The filing signals continued insider alignment with shareholders but entails a small incremental dilution to existing owners.

Punti salienti del Modulo 4 per SELECT MEDICAL HOLDINGS CORP (SEM): Il Vicepresidente Esecutivo Martin F. Jackson ha ricevuto in data 29/07/2025 150.000 azioni ordinarie SEM. Le azioni sono azioni vincolate che matureranno in tre tranche annuali uguali (come indicato nella nota a piè di pagina) e sono state emesse a un prezzo nominale di 0$, indicando un incentivo azionario piuttosto che un acquisto sul mercato aperto.

Dopo l'assegnazione, Jackson detiene ora 1.412.881 azioni direttamente. Inoltre, dichiara 10.536 azioni detenute indirettamente a beneficio dei suoi figli, che nega tranne per eventuali interessi pecuniari.

Non sono stati riportati strumenti derivati nella Tabella II e non si sono verificate vendite, quindi la transazione è esclusivamente una concessione azionaria. La comunicazione segnala un continuo allineamento degli insider con gli azionisti, pur comportando una piccola diluizione incrementale per i proprietari esistenti.

Puntos destacados del Formulario 4 para SELECT MEDICAL HOLDINGS CORP (SEM): El Vicepresidente Ejecutivo Martin F. Jackson recibió el 29/07/2025 150,000 acciones ordinarias de SEM. Las acciones son acciones restringidas que se liberarán en tres tramos anuales iguales (según la nota al pie) y fueron emitidas a un precio declarado de $0, lo que indica un incentivo de capital en lugar de una compra en el mercado abierto.

Tras la adjudicación, Jackson posee ahora 1,412,881 acciones directamente. Además, informa 10,536 acciones mantenidas indirectamente en beneficio de sus hijos, las cuales renuncia salvo por cualquier interés pecuniario.

No se reportaron valores derivados en la Tabla II ni se realizaron ventas, por lo que la transacción es únicamente una concesión de acciones. La presentación señala una alineación continua de los insiders con los accionistas, aunque implica una pequeña dilución incremental para los propietarios existentes.

SELECT MEDICAL HOLDINGS CORP (SEM)의 Form 4 주요 내용: 부사장 Martin F. Jackson이 2025년 7월 29일에 SEM 보통주 150,000주를 부여받았습니다. 이 주식은 3년간 매년 동일한 비율로 권리확정되는 제한주식이며(각주 참조) 명시된 가격은 $0로, 이는 공개 시장에서의 구매가 아닌 주식 인센티브임을 나타냅니다.

수여 후 Jackson은 현재 직접 1,412,881주를 보유하고 있습니다. 또한, 자녀들을 위해 간접적으로 보유한 10,536주도 신고했으며, 금전적 이익을 제외하고는 권리를 포기한다고 밝혔습니다.

표 II에 파생 증권은 보고되지 않았고 매도도 없었으므로, 이번 거래는 순수한 주식 부여입니다. 이 신고는 내부자와 주주 간의 지속적인 일치를 나타내며, 기존 소유자에게는 소량의 희석 효과가 발생합니다.

Points clés du Formulaire 4 pour SELECT MEDICAL HOLDINGS CORP (SEM) : Le Vice-Président Exécutif Martin F. Jackson s'est vu attribuer le 29/07/2025 150 000 actions ordinaires SEM. Ces actions sont des actions restreintes qui seront acquises en trois tranches annuelles égales (selon la note en bas de page) et ont été émises à un prix déclaré de 0 $, indiquant une incitation en actions plutôt qu'un achat sur le marché libre.

Suite à cette attribution, Jackson détient désormais 1 412 881 actions directement. De plus, il déclare 10 536 actions détenues indirectement au bénéfice de ses enfants, dont il renonce sauf pour tout intérêt pécuniaire.

Aucun titre dérivé n'a été signalé dans le Tableau II et aucune vente n'a eu lieu, la transaction est donc uniquement une attribution d'actions. Le dépôt indique une continuité dans l'alignement des initiés avec les actionnaires, tout en entraînant une légère dilution supplémentaire pour les propriétaires actuels.

Formular 4 Highlights für SELECT MEDICAL HOLDINGS CORP (SEM): Der Executive Vice President Martin F. Jackson erhielt am 29.07.2025 150.000 Aktien der SEM-Stammaktien. Die Aktien sind eingeschränkte Aktien, die in drei gleichen jährlichen Tranchen (laut Fußnote) freigegeben werden und zu einem angegebenen Preis von 0 $ ausgegeben wurden, was auf einen Aktienanreiz und keinen Kauf am freien Markt hinweist.

Nach dieser Zuteilung hält Jackson nun 1.412.881 Aktien direkt. Zusätzlich meldet er 10.536 Aktien, die indirekt zum Nutzen seiner Kinder gehalten werden, auf die er außer einem eventuellen finanziellen Interesse verzichtet.

Es wurden keine Derivate in Tabelle II gemeldet und keine Verkäufe getätigt, sodass die Transaktion ausschließlich eine Aktienzuteilung darstellt. Die Meldung signalisiert eine fortgesetzte Übereinstimmung der Insider mit den Aktionären, bringt jedoch eine geringe zusätzliche Verwässerung für die bestehenden Eigentümer mit sich.

Positive
  • Enhanced management alignment: 150,000-share restricted grant ties EVP compensation to future share performance.
  • No insider selling: Filing records only an award; absence of sales avoids negative sentiment.
Negative
  • Slight dilution: New share issuance marginally increases SEM’s outstanding shares, though the impact appears minor.

Insights

TL;DR: Insider receives 150k restricted shares; boosts alignment, minimal immediate dilution.

The grant increases Jackson’s direct stake to >1.4 million shares, reinforcing long-term incentives because shares vest over three years. No cash outlay or sales were recorded, so the transaction is not a valuation signal but rather part of executive compensation. While any new issuance is dilutive, 150k shares is modest for a company of SEM’s size and unlikely to affect per-share metrics materially. Overall impact on valuation is neutral; insider ownership rise is a mild positive for governance.

Punti salienti del Modulo 4 per SELECT MEDICAL HOLDINGS CORP (SEM): Il Vicepresidente Esecutivo Martin F. Jackson ha ricevuto in data 29/07/2025 150.000 azioni ordinarie SEM. Le azioni sono azioni vincolate che matureranno in tre tranche annuali uguali (come indicato nella nota a piè di pagina) e sono state emesse a un prezzo nominale di 0$, indicando un incentivo azionario piuttosto che un acquisto sul mercato aperto.

Dopo l'assegnazione, Jackson detiene ora 1.412.881 azioni direttamente. Inoltre, dichiara 10.536 azioni detenute indirettamente a beneficio dei suoi figli, che nega tranne per eventuali interessi pecuniari.

Non sono stati riportati strumenti derivati nella Tabella II e non si sono verificate vendite, quindi la transazione è esclusivamente una concessione azionaria. La comunicazione segnala un continuo allineamento degli insider con gli azionisti, pur comportando una piccola diluizione incrementale per i proprietari esistenti.

Puntos destacados del Formulario 4 para SELECT MEDICAL HOLDINGS CORP (SEM): El Vicepresidente Ejecutivo Martin F. Jackson recibió el 29/07/2025 150,000 acciones ordinarias de SEM. Las acciones son acciones restringidas que se liberarán en tres tramos anuales iguales (según la nota al pie) y fueron emitidas a un precio declarado de $0, lo que indica un incentivo de capital en lugar de una compra en el mercado abierto.

Tras la adjudicación, Jackson posee ahora 1,412,881 acciones directamente. Además, informa 10,536 acciones mantenidas indirectamente en beneficio de sus hijos, las cuales renuncia salvo por cualquier interés pecuniario.

No se reportaron valores derivados en la Tabla II ni se realizaron ventas, por lo que la transacción es únicamente una concesión de acciones. La presentación señala una alineación continua de los insiders con los accionistas, aunque implica una pequeña dilución incremental para los propietarios existentes.

SELECT MEDICAL HOLDINGS CORP (SEM)의 Form 4 주요 내용: 부사장 Martin F. Jackson이 2025년 7월 29일에 SEM 보통주 150,000주를 부여받았습니다. 이 주식은 3년간 매년 동일한 비율로 권리확정되는 제한주식이며(각주 참조) 명시된 가격은 $0로, 이는 공개 시장에서의 구매가 아닌 주식 인센티브임을 나타냅니다.

수여 후 Jackson은 현재 직접 1,412,881주를 보유하고 있습니다. 또한, 자녀들을 위해 간접적으로 보유한 10,536주도 신고했으며, 금전적 이익을 제외하고는 권리를 포기한다고 밝혔습니다.

표 II에 파생 증권은 보고되지 않았고 매도도 없었으므로, 이번 거래는 순수한 주식 부여입니다. 이 신고는 내부자와 주주 간의 지속적인 일치를 나타내며, 기존 소유자에게는 소량의 희석 효과가 발생합니다.

Points clés du Formulaire 4 pour SELECT MEDICAL HOLDINGS CORP (SEM) : Le Vice-Président Exécutif Martin F. Jackson s'est vu attribuer le 29/07/2025 150 000 actions ordinaires SEM. Ces actions sont des actions restreintes qui seront acquises en trois tranches annuelles égales (selon la note en bas de page) et ont été émises à un prix déclaré de 0 $, indiquant une incitation en actions plutôt qu'un achat sur le marché libre.

Suite à cette attribution, Jackson détient désormais 1 412 881 actions directement. De plus, il déclare 10 536 actions détenues indirectement au bénéfice de ses enfants, dont il renonce sauf pour tout intérêt pécuniaire.

Aucun titre dérivé n'a été signalé dans le Tableau II et aucune vente n'a eu lieu, la transaction est donc uniquement une attribution d'actions. Le dépôt indique une continuité dans l'alignement des initiés avec les actionnaires, tout en entraînant une légère dilution supplémentaire pour les propriétaires actuels.

Formular 4 Highlights für SELECT MEDICAL HOLDINGS CORP (SEM): Der Executive Vice President Martin F. Jackson erhielt am 29.07.2025 150.000 Aktien der SEM-Stammaktien. Die Aktien sind eingeschränkte Aktien, die in drei gleichen jährlichen Tranchen (laut Fußnote) freigegeben werden und zu einem angegebenen Preis von 0 $ ausgegeben wurden, was auf einen Aktienanreiz und keinen Kauf am freien Markt hinweist.

Nach dieser Zuteilung hält Jackson nun 1.412.881 Aktien direkt. Zusätzlich meldet er 10.536 Aktien, die indirekt zum Nutzen seiner Kinder gehalten werden, auf die er außer einem eventuellen finanziellen Interesse verzichtet.

Es wurden keine Derivate in Tabelle II gemeldet und keine Verkäufe getätigt, sodass die Transaktion ausschließlich eine Aktienzuteilung darstellt. Die Meldung signalisiert eine fortgesetzte Übereinstimmung der Insider mit den Aktionären, bringt jedoch eine geringe zusätzliche Verwässerung für die bestehenden Eigentümer mit sich.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Angelini Laura

(Last) (First) (Middle)
1900-B CARNEGIE AVENUE

(Street)
SANTA ANA CA 92705

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Identiv, Inc. [ INVE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/29/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/29/2025 A 22,659(1) A $0.00 49,679(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Restricted Stock Units granted pursuant to Issuer's 2011 Incentive Compensation Plan vesting 1/12th monthly beginning the vesting commencement date of June 1, 2025. Vested shares will be delivered to the reporting person on the earlier of (i) three years from the initial vesting start date of the award or (ii) the separation of service.
2. Includes an aggregate of 20,771 shares of common stock issuable pursuant to restricted stock units that have not vested.
/s/ Ed Kirnbauer, Attorney in Fact 07/31/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many SEM shares did EVP Martin F. Jackson receive?

He was granted 150,000 restricted shares on 07/29/2025.

What is the vesting schedule for the new SEM restricted stock grant?

The shares vest in three equal annual installments over three years.

How many SEM shares does Jackson own after the transaction?

He directly owns 1,412,881 shares and indirectly reports 10,536 shares through family holdings.

Were any SEM shares sold in this Form 4 filing?

No. The filing only reports an award of restricted stock; there were no sales.

Does the Form 4 include any derivative securities like options or warrants?

Table II lists no derivative securities; the transaction involves common stock only.
Identiv

NASDAQ:INVE

INVE Rankings

INVE Latest News

INVE Latest SEC Filings

INVE Stock Data

81.48M
20.64M
13.1%
58.57%
0.66%
Building Products & Equipment
Computer Peripheral Equipment, Nec
Link
United States
SANTA ANA